What separates this from the usual comparison
Most pages here set a research compound beside the prescription route it lacks: what a pharmacy would have guaranteed, what a label would have specified, what a trial would eventually settle. That last item is usually the one piece of forward motion available, because a registered trial at least means somebody is measuring something.
This compound does not have that. The comparison runs out earlier than usual, and the reason is worth showing rather than asserting.
The literature is smaller than the search suggests
PubMed returns around twelve records for the name. Read the titles and the majority concern bronchogenic cysts and bronchogenic carcinoma, which are unrelated conditions that share a word stem with the peptide. A 1989 neonatal cyst, a 2006 laparoscopic extirpation, a 1988 carcinoma report.
Filtered to the compound, the record is about three papers: a 2011 study of the peptide's effect on DNA thermostability, which is also where the sequence is stated; a 2015 study of bronchial epithelium in rats with induced obstructive lung pathology; and a 2017 Russian-language paper on anti-inflammatory and regenerative effects in the same rat model.
In vitro and rats. Nothing in a person.
The registry entry belongs to something else
ClinicalTrials.gov returns one record, and this is where a reader comparing against the prescription market would normally find the thing to wait for.
It is NCT00746759, “Airway Epithelium Gene Expression in the Diagnosis of Lung Cancer: AEGIS IDE”, sponsored by Allegro Diagnostics. The study type is observational. The listed intervention is a diagnostic device, and the record marks it as not used as an intervention. Its purpose is finding gene expression signatures in the airways of smokers that flag lung cancer earlier.
Allegro used the name BronchoGen for a diagnostic test. The search matched the string. A prescription medicine reaches the market through a chain of trials, a label and a regulator's sign-off, and for this compound the first link in that chain does not exist. A fuller reference on the compound and how it is sold is available in this guide to the bronchogen peptide.
What the comparison leaves you with
A published sequence, three animal and in vitro papers, no human data, no approval in any market, no pharmacy route, and no registered study whose result would change any of that.
That is not an argument that the compound does nothing. It is a statement about what is currently knowable, and the gap between that and how the compound is marketed is the whole point of making the comparison.